

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
06 September 2024 (06.09.2024)



(10) International Publication Number
WO 2024/182753 A3

(51) International Patent Classification:

C07D 309/28 (2006.01) *A61P 31/16* (2006.01)
A61K 31/196 (2006.01) *A61K 31/35* (2006.01)
A61K 47/68 (2017.01) *A61K 45/06* (2006.01)
A61P 31/12 (2006.01)

RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2024/018179

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

(22) International Filing Date:

01 March 2024 (01.03.2024)

Published:

— with international search report (Art. 21(3))
— with sequence listing part of description (Rule 5.2(a))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/487,832 01 March 2023 (01.03.2023) US
63/463,664 03 May 2023 (03.05.2023) US
63/539,451 20 September 2023 (20.09.2023) US
63/603,957 29 November 2023 (29.11.2023) US

(88) Date of publication of the international search report:

31 October 2024 (31.10.2024)

(71) Applicant: **CIDARA THERAPEUTICS, INC.** [US/US];
6310 Nancy Ridge Drive, Suite 101, San Diego, CA 92121 (US).

(72) Inventors: **EQUILS, Ozlem, K.**; 4546 Grange Road, Santa Rosa, CA 95404 (US). **FLANAGAN, Shawn, D.**; 2523 Park Ridge Dr, Escondido, CA 92025 (US). **ONG, Voon**; 13966 Royal Melbourne Square, San Diego, CA 92128 (US). **SANDISON, Taylor**; 1042 Third Street, Encinitas, CA 92024 (US).

(74) Agent: **BELLIVEAU, Michael, J.** et al.; Clark & Elbing LLP, 101 Federal Street, 15th Floor, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,

(54) Title: METHODS FOR TREATING INFLUENZA INFECTIONS

(57) Abstract: Provided herein are methods for inhibiting, reducing, or shortening influenza viral replication or infection in a human subject as well as methods for treating influenza infections or related conditions thereto in a human subject in need thereof. The methods include the administration of a zanamivir-Fc conjugate having the structure of Formula (I) in a dosage of 10 to 900 mg.

WO 2024/182753 A3